Lukas Lfling

List of Publications by Citations

Source: https://exaly.com/author-pdf/3703594/lukas-lofling-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8 papers 25 h-index 9-index

10 54 ext. papers ext. citations 4.6 avg, IF L-index

#	Paper	IF	Citations
8	Clinical characteristics and survival in non-small cell lung cancer patients by smoking history: a population-based cohort study. <i>Acta Oncolgica</i> , 2019 , 58, 1618-1627	3.2	8
7	Patterns of prescription dispensation and over-the-counter medication sales in Sweden during the COVID-19 pandemic. <i>PLoS ONE</i> , 2021 , 16, e0253944	3.7	6
6	Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer. <i>Clinical Epidemiology</i> , 2019 , 11, 133-143	5.9	3
5	Maternal and infant characteristics: differences and similarities between the Nordic countries and the US. <i>Clinical Epidemiology</i> , 2016 , 8, 285-94	5.9	3
4	Antibiotic use prior to a lung cancer diagnosis: a population-based study. <i>Cancer Causes and Control</i> , 2021 , 32, 597-607	2.8	2
3	Pharmacological agents preceding a diagnosis of immune thrombocytopenia in adult patients developing the chronic form: A Swedish national register study. <i>Thrombosis Research</i> , 2017 , 160, 27-31	8.2	1
2	Temporal trends in lung cancer survival: a population-based study. <i>Acta Oncolgica</i> , 2021 , 1-7	3.2	1
1	Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 758-769	2.6	0